Insider Selling: Beigene Ltd (BGNE) Director Sells 15,027 Shares of Stock
Beigene Ltd (NASDAQ:BGNE) Director Donald W. Glazer sold 15,027 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $125.11, for a total value of $1,880,027.97. Following the transaction, the director now directly owns 3,911,518 shares of the company’s stock, valued at $489,370,016.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
BGNE traded up $4.40 on Thursday, hitting $137.85. 126,685 shares of the company were exchanged, compared to its average volume of 345,493. Beigene Ltd has a 12 month low of $105.19 and a 12 month high of $220.10. The firm has a market capitalization of $8.21 billion, a PE ratio of -11.35 and a beta of 1.07. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.47 and a current ratio of 7.52.
Beigene (NASDAQ:BGNE) last released its earnings results on Thursday, May 9th. The company reported ($2.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.15) by $0.34. Beigene had a negative return on equity of 44.75% and a negative net margin of 302.58%. The business had revenue of $77.83 million for the quarter, compared to analyst estimates of $55.79 million. During the same quarter in the prior year, the company posted ($2.03) earnings per share. Beigene’s revenue was up 139.2% on a year-over-year basis. On average, research analysts forecast that Beigene Ltd will post -13.27 earnings per share for the current year.
Several research analysts have recently weighed in on BGNE shares. Zacks Investment Research raised Beigene from a “hold” rating to a “buy” rating and set a $149.00 price objective for the company in a research report on Wednesday. BidaskClub raised Beigene from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. Bank of America started coverage on Beigene in a research report on Friday, March 15th. They set a “buy” rating and a $200.00 price objective for the company. Maxim Group set a $170.00 price objective on Beigene and gave the stock a “buy” rating in a research report on Thursday, February 28th. Finally, ValuEngine cut Beigene from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 15th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Beigene has an average rating of “Buy” and a consensus price target of $182.34.
TRADEMARK VIOLATION WARNING: This report was first published by Marea Informative and is owned by of Marea Informative. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.mareainformativa.com/news/2019/05/16/insider-selling-beigene-ltd-bgne-director-sells-15027-shares-of-stock.html.
Beigene Company Profile
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.